Martine A. Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ:UTHR), was involved in several transactions concerning the company's common stock recently. On May 28, 2026, Ms. Rothblatt exercised her stock options to acquire an additional 9,500 shares of the company's stock. Following the acquisition, she proceeded to sell all 9,500 shares, realizing total proceeds valued at approximately $5.37 million.
The details of this sale indicate that the 9,500 shares were sold across a price range spanning from $561.00 to $571.65 per share. These transactions generated total proceeds amounting to $5,373,592 for Ms. Rothblatt. It is noted that prior to executing these sales, she had acquired the 9,500 shares through the exercise of stock options at a cost of $146.03 per share, totaling $1,387,285 in acquisition costs.
All reported transactions were managed under the framework of a pre-arranged 10b5-1 trading plan. Ms. Rothblatt originally adopted this specific plan on November 7, 2025. The terms of this existing plan stipulate that it will remain active until one of two events occurs: either 1,734,410 stock options have been exercised, or the date reaches December 31, 2026, whichever event happens first.
Beyond her personal transactions, United Therapeutics continues to present several key operational and financial developments. According to an analysis by InvestingPro, the company maintains solid underlying financial fundamentals, citing an impressive gross profit margin of 87% and reporting that its balance sheet holds more cash than debt. However, the platform's Fair Value assessment suggests that, despite these strengths, the stock may currently be overvalued based on existing market data.
As for her current holdings, following the May 28 transactions, Ms. Rothblatt directly owns 40,513 shares of United Therapeutics common stock. Her total indirect stake is more complex, involving various family trusts and her spouse. These indirect holdings include specific allocations: 166 shares held by her spouse; 324,443 shares within family trusts where she retains shared investment power; 249,108 shares in family trusts where her spouse serves as the sole or co-trustee with revocation power; 45,596 shares in family trusts where her spouse shares investment power; and finally, 8,902 shares in family trusts where she is the sole or co-trustee with revocation power.
Risks
- Market valuation concerns, as the platform's Fair Value assessment suggests UTHR may be overvalued at current levels.
- Mixed financial results in Q1, with revenue ($781.5 million) and net income ($274.9 million) missing expected consensus estimates.
More from Insider Trading
Risks
- Market valuation concerns, as the platform's Fair Value assessment suggests UTHR may be overvalued at current levels.
- Mixed financial results in Q1, with revenue ($781.5 million) and net income ($274.9 million) missing expected consensus estimates.